Cereno’s CEO: “very excited for topline readout!”

29 August, 2024

Cereno’s CEO: “very excited for topline readout!”

29 August, 2024

Cereno Scientific has released its Q2 report for 2024, highlighting the company’s advancements in developing cardiovascular disease treatments. CEO Sten R Sörensen came by the BioStock Studio to discuss the main takeaways from the period and take a sneak peak into what’s to come for the company during Q3.

Watch the interview with Cereno Scientific’s CEO Sten R Sörensen below:

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.